Drug intelligence / Profile preview

CLP-417

Development stage: Unknown
Lead developer: Charleston Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**CLP-417** is an investigational oral fixed-dose small-molecule combination developed by Charleston Pharma for moderate-to-severe acute pain and prevention or reduction of opioid-induced nausea and vomiting. It combines modified-release tramadol, an opioid analgesic and monoamine reuptake inhibitor, with rapid-release promethazine, an H1 antihistamine with antiemetic dopamine-receptor antagonist activity. The product is designed to provide analgesia while mitigating nausea and vomiting associated with opioid therapy.

Other names: promethazine + tramadoltramadol + promethazine

Targets

HRH1 (Histamine H1 Receptor)NET (Norepinephrine Transporter)DRD2 (Dopamine D2 Receptor)MOR (Mu opioid receptor)mAChR (Muscarinic acetylcholine receptors)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on CLP-417.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLP-417.

Explore the full profile